MacroGenics raises $45 million in series C financing

By Elaine Rigoli

Tampa, Fla., May 17 - MacroGenics, Inc. has raised $45 million in a series C financing round.

The financing, led by Ventures West, included new investment groups Caisse de depot et placement du Quebec, RiverVest Venture Partners and Biogen Idec New Ventures. Also participating in the round were Texas Pacific Group Ventures, Alta Partners, InterWest Partners, MPM Capital, Mithra Ventures, OrbiMed Advisors and Red Abbey Venture Partners, all previous investors in MacroGenics.

The company said it plans to use a significant portion of the money to support an international phase 2/3 trial of MacroGenics' lead product candidate, a CD3 monoclonal antibody for type 1 diabetes mellitus, and to advance treatments for other autoimmune diseases such as arthritis and multiple sclerosis.

MacroGenics is a private, venture-backed biotechnology company with headquarters in Rockville, Md., that focuses on the development of immunotherapeutics for autoimmune disorders, cancer and infectious diseases.

Issuer:	MacroGenics, Inc.
Issue:	Series C financing
Amount:	$45 million
Investors:	Ventures West, Caisse de depot et placement du Quebec, RiverVest Venture Partners, Biogen Idec New Ventures, Texas Pacific Group Ventures, Alta Partners, InterWest Partners, MPM Capital, Mithra Ventures, OrbiMed Advisors and Red Abbey Venture Partners
Announcement date:	May 17

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.